These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34083286)

  • 1.
    Drikos I; Boutou E; Kastritis PL; Vorgias CE
    Anticancer Res; 2021 Jun; 41(6):2953-2962. PubMed ID: 34083286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.
    Drikos I; Nounesis G; Vorgias CE
    Proteins; 2009 Nov; 77(2):464-76. PubMed ID: 19452558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
    Tischkowitz M; Hamel N; Carvalho MA; Birrane G; Soni A; van Beers EH; Joosse SA; Wong N; Novak D; Quenneville LA; Grist SA; ; Nederlof PM; Goldgar DE; Tavtigian SV; Monteiro AN; Ladias JA; Foulkes WD
    Eur J Hum Genet; 2008 Jul; 16(7):820-32. PubMed ID: 18285836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains.
    Rodriguez M; Yu X; Chen J; Songyang Z
    J Biol Chem; 2003 Dec; 278(52):52914-8. PubMed ID: 14578343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition.
    Coquelle N; Green R; Glover JN
    Biochemistry; 2011 May; 50(21):4579-89. PubMed ID: 21473589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of
    Petitalot A; Dardillac E; Jacquet E; Nhiri N; Guirouilh-Barbat J; Julien P; Bouazzaoui I; Bonte D; Feunteun J; Schnell JA; Lafitte P; Aude JC; Noguès C; Rouleau E; Lidereau R; Lopez BS; Zinn-Justin S; Caputo SM;
    Mol Cancer Res; 2019 Jan; 17(1):54-69. PubMed ID: 30257991
    [No Abstract]   [Full Text] [Related]  

  • 7. Phosphopeptide interactions with BRCA1 BRCT domains: More than just a motif.
    Wu Q; Jubb H; Blundell TL
    Prog Biophys Mol Biol; 2015 Mar; 117(2-3):143-148. PubMed ID: 25701377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation.
    Williams RS; Glover JN
    J Biol Chem; 2003 Jan; 278(4):2630-5. PubMed ID: 12427738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of RING and BRCT domain mutations on BRCA1 protein stability, localization and recruitment to DNA damage.
    Nelson AC; Holt JT
    Radiat Res; 2010 Jul; 174(1):1-13. PubMed ID: 20681793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of cancer related BRCA1 missense variants decreases MMS-induced recombination in Saccharomyces cerevisiae without altering its nuclear localization.
    Lodovichi S; Vitello M; Cervelli T; Galli A
    Cell Cycle; 2016 Oct; 15(20):2723-31. PubMed ID: 27484786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter-BRCT linker is probably the most intolerant region of the BRCA1 BRCT domain.
    Yadegari F; Farahmand L; Esmaeili R; Zarinfam S; Majidzadeh-A K
    J Biomol Struct Dyn; 2024 Jul; 42(11):5734-5746. PubMed ID: 37948190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BRCA1 RING and BRCT domains cooperate in targeting BRCA1 to ionizing radiation-induced nuclear foci.
    Au WW; Henderson BR
    J Biol Chem; 2005 Feb; 280(8):6993-7001. PubMed ID: 15569676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer predisposing mutations in BRCT domains.
    di Masi A; Gullotta F; Cappadonna V; Leboffe L; Ascenzi P
    IUBMB Life; 2011 Jul; 63(7):503-12. PubMed ID: 21698754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations.
    Williams RS; Chasman DI; Hau DD; Hui B; Lau AY; Glover JN
    J Biol Chem; 2003 Dec; 278(52):53007-16. PubMed ID: 14534301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain.
    Rodriguez JA; Au WW; Henderson BR
    Exp Cell Res; 2004 Feb; 293(1):14-21. PubMed ID: 14729053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on human transcriptome of mutated BRCA1 BRCT domain: a microarray study.
    Iofrida C; Melissari E; Mariotti V; Guglielmi C; Guidugli L; Caligo MA; Pellegrini S
    BMC Cancer; 2012 May; 12():207. PubMed ID: 22646717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thermal denaturation of the BRCT tandem repeat region of human tumour suppressor gene product BRCA1.
    Pyrpassopoulos S; Ladopoulou A; Vlassi M; Papanikolau Y; Vorgias CE; Yannoukakos D; Nounesis G
    Biophys Chem; 2005 Apr; 114(1):1-12. PubMed ID: 15792855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BRCT domain is a phospho-protein binding domain.
    Yu X; Chini CC; He M; Mer G; Chen J
    Science; 2003 Oct; 302(5645):639-42. PubMed ID: 14576433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains.
    Magnard C; Bachelier R; Vincent A; Jaquinod M; Kieffer S; Lenoir GM; Venezia ND
    Oncogene; 2002 Oct; 21(44):6729-39. PubMed ID: 12360400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.
    Lee MS; Green R; Marsillac SM; Coquelle N; Williams RS; Yeung T; Foo D; Hau DD; Hui B; Monteiro AN; Glover JN
    Cancer Res; 2010 Jun; 70(12):4880-90. PubMed ID: 20516115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.